Non-antipsychotic catecholaminergic drugs for antipsychotic-induced tardive dyskinesia Author El-Sayeh, Hany G, Rathbone, John, Soares-Weiser, Karla, Bergman, Hanna Published 2018 Journal Title Cochrane Database of Systematic Reviews Version Version of Record (VoR) DOI https://doi.org/10.1002/14651858.CD000458.pub3 Copyright Statement © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. This review is published as a Cochrane Review in the Cochrane Database of Systematic Reviews 2018, Issue 1. Art. No.: CD000458. Cochrane Reviews are regularly updated as new evidence emerges and in response to comments and criticisms, and the Cochrane Database of Systematic Reviews should be consulted for the most recent version of the Review. Downloaded from http://hdl.handle.net/10072/391153 Griffith Research Online https://research-repository.griffith.edu.au Cochrane Library Cochrane Database of Systematic Reviews Non-antipsychotic catecholaminergic drugs for antipsychotic- induced tardive dyskinesia (Review) El-Sayeh HG, Rathbone J, Soares-Weiser K, Bergman H El-Sayeh HG, Rathbone J, Soares-Weiser K, Bergman H. Non-antipsychotic catecholaminergic drugs for antipsychotic-induced tardive dyskinesia. Cochrane Database of Systematic Reviews 2018, Issue 1. Art. No.: CD000458. DOI: 10.1002/14651858.CD000458.pub3. www.cochranelibrary.com Non-antipsychotic catecholaminergic drugs for antipsychotic-induced tardive dyskinesia (Review) Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. Cochrane Trusted evidence. Informed decisions. Library Better health. Cochrane Database of Systematic Reviews T A B L E O F C O N T E N T S HEADER......................................................................................................................................................................................................... 1 ABSTRACT..................................................................................................................................................................................................... 1 PLAIN LANGUAGE SUMMARY....................................................................................................................................................................... 2 SUMMARY OF FINDINGS.............................................................................................................................................................................. 4 BACKGROUND.............................................................................................................................................................................................. 10 OBJECTIVES.................................................................................................................................................................................................. 11 METHODS..................................................................................................................................................................................................... 11 Figure 1.................................................................................................................................................................................................. 13 Figure 2.................................................................................................................................................................................................. 15 Figure 3.................................................................................................................................................................................................. 16 RESULTS........................................................................................................................................................................................................ 19 Figure 4.................................................................................................................................................................................................. 20 DISCUSSION.................................................................................................................................................................................................. 26 AUTHORS' CONCLUSIONS........................................................................................................................................................................... 27 ACKNOWLEDGEMENTS................................................................................................................................................................................ 28 REFERENCES................................................................................................................................................................................................ 29 CHARACTERISTICS OF STUDIES.................................................................................................................................................................. 35 DATA AND ANALYSES.................................................................................................................................................................................... 53 Analysis 1.1. Comparison 1 NORADRENERGIC DRUGS vs PLACEBO, Outcome 1 Tardive dyskinesia: 1. No clinically important 54 improvement - short term.................................................................................................................................................................... Analysis 1.2. Comparison 1 NORADRENERGIC DRUGS vs PLACEBO, Outcome 2 Tardive dyskinesia: 2. Not any improvement....... 54 Analysis 1.3. Comparison 1 NORADRENERGIC DRUGS vs PLACEBO, Outcome 3 Tardive dyskinesia: 3. Deterioration - short term.... 55 Analysis 1.4. Comparison 1 NORADRENERGIC DRUGS vs PLACEBO, Outcome 4 Acceptability of treatment: Leaving the study 55 early - medium term............................................................................................................................................................................. Analysis 1.5. Comparison 1 NORADRENERGIC DRUGS vs PLACEBO, Outcome 5 Quality of life: No improvement - medium term.... 56 Analysis 2.1. Comparison 2 NORADRENERGIC DRUGS vs DOPAMINERGIC DRUGS, Outcome 1 Tardive dyskinesia: 1. No clinically 56 important improvement - short term.................................................................................................................................................. Analysis 2.2. Comparison 2 NORADRENERGIC DRUGS vs DOPAMINERGIC DRUGS, Outcome 2 Tardive dyskinesia: 2. Not any 57 improvement - short term.................................................................................................................................................................... Analysis 2.3. Comparison 2 NORADRENERGIC DRUGS vs DOPAMINERGIC DRUGS, Outcome 3 Tardive dyskinesia: 3. Deterioration 57 - short term........................................................................................................................................................................................... Analysis 3.1. Comparison 3 DOPAMINERGIC DRUGS vs PLACEBO, Outcome 1 Tardive dyskinesia: 1. No clinically important 59 improvement......................................................................................................................................................................................... Analysis 3.2. Comparison 3 DOPAMINERGIC DRUGS vs PLACEBO, Outcome 2 Tardive dyskinesia: 2. Not any improvement......... 59 Analysis 3.3. Comparison 3 DOPAMINERGIC DRUGS vs PLACEBO, Outcome 3 Tardive dyskinesia: 3. Deterioration....................... 60 Analysis 3.4. Comparison 3 DOPAMINERGIC DRUGS vs PLACEBO, Outcome 4 Mental state: Deterioration - medium term........... 60 Analysis 3.5. Comparison 3 DOPAMINERGIC DRUGS vs PLACEBO, Outcome 5 Acceptability of treatment: Leaving the study 60 early........................................................................................................................................................................................................ Analysis 4.1. Comparison 4 DOPAMINERGIC DRUGS vs OTHER DRUGS, Outcome 1 Tardive dyskinesia: 1. No clinically important 62 improvement - medium term.............................................................................................................................................................. Analysis 4.2. Comparison 4 DOPAMINERGIC DRUGS vs OTHER DRUGS, Outcome 2 Tardive dyskinesia: 2. Not any improvement 62 - medium term...................................................................................................................................................................................... Analysis 4.3. Comparison 4 DOPAMINERGIC DRUGS vs OTHER DRUGS, Outcome 3 Tardive dyskinesia: 3. Deterioration - medium 63 term........................................................................................................................................................................................................ Analysis 4.4. Comparison 4 DOPAMINERGIC DRUGS vs OTHER DRUGS, Outcome 4 Acceptability of treatment: Leaving the study 63 early - medium term............................................................................................................................................................................. ADDITIONAL TABLES...................................................................................................................................................................................